GlycoNex, Inc. (4168), a Taiwan-based clinical-stage biotechnology company, announced on April 14 that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has cleared the initiation of a first-in-human Phase I trial of GNX1021, its lead antibody-drug conjugate (ADC) candidate, in patients with advanced gastrointestinal cancers. Enrollment at Japanese sites is expected to begin in June 2026, with a Taiwan IND submission planned for the same month and enrollment there anticipated in the third quarter of 2026.
The multicenter Phase I study will evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of GNX1021 across dose escalation cohorts, with the primary objective of establishing a recommended dose for subsequent development. Patient numbers, specific endpoints beyond dose-finding, and an anticipated completion date have not been disclosed. GNX1021 targets the bLeB/Y antigen, a branched glycan structure abnormally overexpressed on the surface of epithelial tumor cells, including those of gastric, pancreatic, and colorectal origin, while showing limited expression in normal tissue.
The molecule's mechanism departs from conventional ADC design. Rather than coupling a cytotoxic payload to an antibody directed at a single protein epitope, GNX1021 exploits aberrant glycosylation patterns shared across multiple tumor-associated membrane proteins. This multi-target engagement is intended to reduce the escape routes available to heterogeneous tumor cell populations — a problem that has constrained the durability of responses seen with single-target agents in gastric cancer. GlycoNex published preclinical data for the molecule at the American Association for Cancer Research (AACR) Annual Meeting 2025.
Research context
The biological rationale for glycan-directed therapy in gastrointestinal malignancies rests on a well-characterized feature of cancer cell biology: aberrant glycosylation. Tumor cells frequently display truncated or branched carbohydrate structures — including Lewis blood group-related antigens such as the bLeB/Y epitope — that are absent or minimally expressed on healthy epithelium. This differential expression creates a targeting window that protein-directed therapies cannot exploit when the relevant protein is also present on normal tissue. The ADC format allows GlycoNex to combine this selectivity with direct cytotoxic delivery, potentially improving the therapeutic index relative to unconjugated antibodies.